Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1325-1336. PMID: 35918106, PMCID: PMC9625096, DOI: 10.2215/cjn.00550122.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsTimes weekly dosingTRIAL REGISTRY NAMESecondary end pointsTreatment of anemiaEpoetin groupDaprodustat groupEnd pointWeekly dosingREGISTRY NAMEHemoglobin valuesMean changeHypoxia-inducible factor prolyl hydroxylase inhibitorCLINICAL TRIAL REGISTRY NAMEPrincipal secondary end pointTreatment-emergent adverse eventsIntravenous iron doseIntravenous iron usePrimary end pointChronic kidney diseaseMean hemoglobin valuesEvaluation periodProlyl hydroxylase inhibitorBaseline hemoglobinPrevalent hemodialysis